BDRX: Biodexa Pharma Broker Consensus Forecast

Biodexa Pharmaceuticals (BDRX) focuses on developing high-precision drug delivery methods for combating brain tumors that overcome biological barriers. The business is independent of economic fluctuations, relying instead on the success of clinical trials. This price chart reflects a current indicator at 71.76. To mitigate the risks of narrow specialization, the firm is implementing licensing agreements with pharmacy chains to expand access to its formulas.

BDRX: Biodexa Pharma Consensus Target 04/28/2023 - 11/11/2026

Analytical breakdowns for Biodexa Pharmaceuticals (BDRX)

- current price and projected stock value:

Price Chart biodexapharma.com|BDRX - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Biodexa Pharma|BDRX - Total Company Value

- business book valuation details:

Accounting Value of a Share Biodexa Pharmaceuticals|BDRX - Company Net Assets|Capitalization to Book Value Ratio biodexapharma.com|BDRX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

Aggregate Debt to Equity Biodexa Pharmaceuticals|BDRX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital biodexapharma.com|BDRX - Company Aggregate Debts|Debts to Book Capitalization Biodexa Pharma|BDRX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Biodexa Pharmaceuticals|Quick Liquidity Indicator biodexapharma.com

- earnings and valuation multiples information:

BDRX - Net Profit|Projected Future Earnings Biodexa Pharmaceuticals|BDRX - P/E Multiple|Projected Price to Earnings biodexapharma.com|BDRX - Price/Earnings to Growth Multiple|Company Value to EBITDA Biodexa Pharma|BDRX - Operating profit EBITDA|Earnings per share for the last twelve months Biodexa Pharmaceuticals|BDRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months biodexapharma.com|BDRX - Earnings per share growth in current year|Expected net earnings per share growth next year Biodexa Pharmaceuticals

General company analysis:BDRX Biodexa

Flagship merchandise of Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals (BDRX) operates in a capital-burn mode without current revenue, making its valuation dependent on expectations for future research. The aggregated target price from investment houses reflects the weighted average fair value of the asset, allowing the analyst target consensus for the stock to determine whether the current correction is market noise or a systemic revision of the biopharma startup's fundamental attractiveness.

Competitors of Biodexa Pharmaceuticals